Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Industries

Generic drug approvals boost pharma firms' global ambitions

By Liu Zhihua | China Daily | Updated: 2019-03-07 11:42
Share
Share - WeChat
Many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. [Photo/VCG]

Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.

According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.

The number was 38 in 2017 and 22 in 2016. Before 2016, Chinese pharmaceutical companies had fewer than 15 ANDAs approved on average each year.

A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.

Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.

The company announced earlier that the first batch of the drug was about to be delivered to the US market.

The think tank said one reason behind the rise in approvals is that many Chinese pharmaceutical companies are able and need to go global, especially the leading ones. Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.

In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality. Failure to pass the evaluation before the required deadline leads to revocation of the drug title's registration license or ineligibility for government tendering. Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.

Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, added that the Chinese authorities' recent policies are very supportive of innovation and high-quality generic drug research and development, providing solid incentives for Chinese pharmaceutical companies to file more ANDAs.

"If a Chinese generic drug gains US approval, it is often fast tracked by Chinese authorities when it applies for domestic approval, giving it an advantage in the fiercely competitive domestic generic drug market," he said.

Shen Yaping, vice-president with Jiangsu Hengrui Medicine Co Ltd, a top Chinese pharmaceutical company listed in Shanghai, said the company now files new generic drug applications to domestic and US authorities for this reason.

"Going global and innovation are the two most important development strategies for our company, and now we feel encouraged, because a lot of government policies are inspiring to companies like us that want to expand overseas business," Shen said.

The overseas markets, especially the US, are large and alluring, yet in the past, Chinese pharmaceutical companies lacked the ability to expand overseas, he said, adding that as a number of first-tier Chinese pharmaceutical companies have succeeded in developing overseas business, others are trying to keep up with them.

His company and its subsidiary Shanghai Hengrui Pharmaceutical Co Ltd have received 16 ANDA approvals, according to its website.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 人人添人人妻人人爽夜欢视av| 国产精品水嫩水嫩| 久热综合在线亚洲精品| 狠狠色综合网站久久久久久久| 日本一区二区三区在线观看| 亚洲精品成人片在线播放| 日本网址在线观看| 无码精品人妻一区二区三区影院 | 国产剧情一区二区| 久久国产乱子伦免费精品| 激情图片小说网| 国产欧美第一页| chinese国产xxxx实拍| 欧美国产永久免费看片| 午夜亚洲av永久无码精品| 777奇米影视网| 影音先锋无码a∨男人资源站| 亚洲欧美国产精品完整版| 香港国产特级一级毛片| 少妇被又大又粗又爽毛片久久黑人 | 亚洲欧美日韩精品久久亚洲区| 老公说我是不是欠g了| 国产日韩精品欧美一区| 久久久久久久亚洲AV无码 | 久久精品国内一区二区三区| 精品国产成人亚洲午夜福利| 国产自无码视频在线观看| 一级特色大黄美女播放网站| 欧美国产在线视频| 你好老叔电影观看免费| 四虎免费影院ww4164h| 夜夜夜夜猛噜噜噜噜噜试看| 中国毛片免费看| 欧美成人在线网站| 先锋影音av资源网| 欧美欧洲性色老头老妇| 国语对白刺激做受xxxxx在线| 一级黄色免费网站| 日本三级做a全过程在线观看| 亚洲gv天堂gv无码男同| 综合网中文字幕|